Literature DB >> 15647861

Mechanism of action and emerging role of immune response modifier therapy in dermatologic conditions.

Daniel N Sauder1.   

Abstract

Immune response modifiers (IRMs) are agents that target the body's immune system (i.e., cytokines, receptors, and inflammatory cells) to combat disease. Topical IRM therapies, which encompass both proinflammatory and immunosuppressive therapeutics, have been used to successfully treat a number of dermatologic conditions. Proinflammatory treatments include Toll-like receptor agonists (e.g., imiquimod 5% cream) and interferon (e.g., interferon-alpha) therapies, which have been used in the treatment of external genital warts, basal cell carcinoma, and other dermatologic diseases. Immunosuppressive therapies include topical and intralesional corticosteroids, anti-tumor necrosis factor agents (e.g., infliximab and etanercept), and anti-CD4+ T-cell agents, including calcineurin inhibitors and mycophenolate. These agents have been used to treat a number of conditions, including atopic and seborrheic dermatitis and psoriasis. This article reviews the mechanism of action of IRMs and the application of IRMs in several dermatologic diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15647861     DOI: 10.1007/s10227-004-0803-3

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN: 1203-4754            Impact factor:   2.092


  4 in total

1.  A case of severe eczema following use of imiquimod 5% cream.

Authors:  C L Taylor; M Maslen; M Kapembwa
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

2.  Keratinocyte apoptosis in epidermal remodeling and clearance of psoriasis induced by UV radiation.

Authors:  Sophie C Weatherhead; Peter M Farr; David Jamieson; Jennifer S Hallinan; James J Lloyd; Anil Wipat; Nick J Reynolds
Journal:  J Invest Dermatol       Date:  2011-05-26       Impact factor: 8.551

3.  Expression of epidermal CAMP changes in parallel with permeability barrier status.

Authors:  Marina Rodriguez-Martin; Gemma Martin-Ezquerra; Mao-Qiang Man; Melanie Hupe; Jong-Kyung Youm; Donald S Mackenzie; Soyun Cho; Carles Trullas; Walter M Holleran; Katherine A Radek; Peter M Elias
Journal:  J Invest Dermatol       Date:  2011-07-28       Impact factor: 8.551

4.  Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study.

Authors:  Raveewan Choontanom; Solon Thanos; Holger Busse; Tobias Stupp
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08       Impact factor: 3.535

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.